Company profile
EXICURE, INC.
NASDAQ:XCURBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CAVROTOLIMOD | phase1_2 | — | 2 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03086278 | phase1 | completed | 2017-10-20 | 2018-08-16 | Exicure, Inc. | A Study of AST-008 in Healthy Subjects |
| NCT03684785 | phase1_2 | terminated | 2018-12-13 | 2022-03-30 | Exicure, Inc. | Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors |
FDA applications (0)
No records yet.